Hallucinations in Parkinson disease
- 1 June 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Neurology
- Vol. 5 (6), 331-342
- https://doi.org/10.1038/nrneurol.2009.62
Abstract
Patients with Parkinson disease (PD) can experience hallucinations (spontaneous aberrant perceptions) and illusions (misinterpretations of real perceptual stimuli). Of such phenomena, visual hallucinations (vHs) and illusions are the most frequently encountered, although auditory, olfactory and tactile hallucinations can also occur. in cross-sectional studies, vHs occur in approximately one-third of patients, but up to three-quarters of patients might develop vHs during a 20-year period. Hallucinations can have substantial psychosocial effects and, historically, were the main reason for placing patients in nursing homes. Concomitant or overlapping mechanisms are probably active during vHs, and these include the following: central dopaminergic overactivity and an imbalance with cholinergic neurotransmission; dysfunction of the visual pathways, including specific PD-associated retinopathy and functional alterations of the extrastriate visual pathways; alterations of brainstem sleep-wake and dream regulation; and impaired attentional focus. Possible treatments include patient-initiated coping strategies, a reduction of antiparkinson medications, atypical neuroleptics and, potentially, cholinesterase inhibitors. evidence-based studies, however, only support the use of one atypical neuroleptic, clozapine, and only in patients without dementia. Better phenomenological discrimination, combined with neuroimaging tools, should refine therapeutic options and improve prognosis. The aim of this review is to present epidemiological, phenomenological, pathophysiological and therapeutic aspects of hallucinations in PD.Keywords
This publication has 143 references indexed in Scilit:
- Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long‐term worseningMovement Disorders, 2008
- Circadian rest‐activity rhythm is altered in Parkinson's disease patients with hallucinationsMovement Disorders, 2008
- Impaired recognition of facial expressions of anger in Parkinson's disease patients acutely withdrawn from dopamine replacement therapyNeuropsychologia, 2007
- Methamphetamine psychosis in which tardive dystonia was successfully treated with clonazepamPsychiatry and Clinical Neurosciences, 2007
- Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genesNeuroscience Letters, 2007
- Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson?s diseaseJournal of Neural Transmission, 2004
- Retinal involvement in dementia with Lewy bodies: A clue to hallucinations?Annals of Neurology, 2003
- Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-upNeurological Sciences, 2002
- Visual hallucinations in psychologically normal people: Charles Bonnet's syndromeThe Lancet, 1996
- Cholinergic and Dopaminergic Activities in Senile Dementia of Lewy Body TypeAlzheimer Disease & Associated Disorders, 1990